Analysis - By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), and End User (Hospitals, Oncology Clinics, Research Centers, and Others)
The Europe lung cancer therapy market was valued at US$ 9,919.66 million in 2022 and is expected to reach US$ 25,548.74 million by 2030; it is estimated to grow at a CAGR of 12.6% from 2022 to 2030.
Government Initiatives for Screening and Treatment of Lung Cancer Drive Europe Lung Cancer Therapy Market
According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer. The Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients. Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the Europe lung cancer therapy market.
Europe Lung Cancer Therapy Market Overview
According to an article titled "Lung Cancer in Germany," published in the Journal of Thoracic Oncology in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. With an age-standardized incidence rate of 52.1% and 32.7% (per 100,000) in men and women, respectively, lung cancer ranks second in men and third in women (accounting for 13.3% and 9.4% of all newly diagnosed cancers, respectively). The average age of cancer diagnosis is 70 years (men) and 69 years (women); 52% of all patients present with stage IV. The incidence rates in women and men have converged since the 1990s because of long-term changes in smoking habits. Currently, every fourth man (27.0%) and every fifth woman (20.8%) in Germany smokes regularly.
The German National Cancer Plan designates organ cancer centers (lung cancer centers), oncology centers, and comprehensive cancer centers to offer general oncologic care in Germany. As of 2020, 64 lung cancer centers at 79 institutions were certified nationwide. Rise in the incidence of lung cancer and an increase in the number of lung cancer centers across Germany are fueling the growth of the market.
Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Million)
Europe Lung Cancer Therapy Market Segmentation
The Europe lung cancer therapy market is segmented based on therapy type, indication, end user, and country.
Based on therapy type, the Europe lung cancer therapy market is bifurcated into noninvasive and minimally invasive. The noninvasive segment held a larger share in 2022. The minimally invasive segment is further subsegmented into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others.
By indication, the Europe lung cancer therapy market is bifurcated into non-small cell lung cancer and small cell lung cancer. The non-small cell lung cancer segment held a larger share in 2022.
By end user, the Europe lung cancer therapy market is segmented into hospitals, oncology clinics, research centers, and others. The hospitals segment held the largest share in 2022.
Based on country, the Europe lung cancer therapy market is segmented into Germany, the UK, France, Italy, Spain, Russia, and the Rest of Europe. Germany dominated the Europe lung cancer therapy market in 2022.
Medtronic Plc, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Olympus Corp, Meiji Seika Pharma Co Ltd, and Advanz Pharma Corp are some of the leading companies operating in the Europe lung cancer therapy market.
Europe Lung Cancer Therapy Market Strategic Insights
Get more information on this report
Europe Lung Cancer Therapy Market Segmentation Analysis
Europe Lung Cancer Therapy Market Report Highlights
Europe Lung Cancer Therapy Report Scope
Report Attribute
Details
Market size in 2022
US$ 9,919.66 Million
Market Size by 2030
US$ 25,548.74 Million
CAGR (2022 - 2030)
12.6%
Historical Data
2020-2021
Forecast period
2023-2030
Segments Covered
By Therapy Type
Noninvasive and Minimally Invasive
By Indication
Non-Small Cell Lung Cancer and Small Cell Lung Cancer
By End User
Hospitals
Oncology Clinics
Research Centers
Regions and Countries Covered
Europe
UK, Germany, France, Russia, Italy, Rest of Europe
Market leaders and key company profiles
Advanz Pharma Corp
Bioventus Inc
Johnson & Johnson
Medtronic Plc
Meiji Seika Pharma Co Ltd
Merck KGaA
Olympus Corp
RF Medical Co Ltd
Sun Pharmaceutical Industries Ltd
Get more information on this report
Europe Lung Cancer Therapy Market Country and Regional Insights
Get more information on this report
Identical Market Reports with other Region/Countries
The List of Companies - Europe Lung Cancer Therapy Market
1. Advanz Pharma Corp
2. Bioventus Inc
3. Johnson & Johnson
4. Medtronic Plc
5. Meiji Seika Pharma Co Ltd
6. Merck KGaA
7. Olympus Corp
8. RF Medical Co Ltd
9. Sun Pharmaceutical Industries Ltd
Frequently Asked Questions
How big is the Europe Lung Cancer Therapy Market?
The Europe Lung Cancer Therapy Market is valued at US$ 9,919.66 Million in 2022, it is projected to reach US$ 25,548.74 Million by 2030.
What is the CAGR for Europe Lung Cancer Therapy Market by (2022 - 2030)?
As per our report Europe Lung Cancer Therapy Market, the market size is valued at US$ 9,919.66 Million in 2022, projecting it to reach US$ 25,548.74 Million by 2030. This translates to a CAGR of approximately 12.6% during the forecast period.
What segments are covered in this report?
The Europe Lung Cancer Therapy Market report typically cover these key segments-
Therapy Type (Noninvasive and Minimally Invasive)
Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer)
End User (Hospitals, Oncology Clinics, Research Centers)
What is the historic period, base year, and forecast period taken for Europe Lung Cancer Therapy Market?
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Lung Cancer Therapy Market report:
Historic Period : 2020-2021
Base Year : 2022
Forecast Period : 2023-2030
Who are the major players in Europe Lung Cancer Therapy Market?
The Europe Lung Cancer Therapy Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
Advanz Pharma Corp
Bioventus Inc
Johnson & Johnson
Medtronic Plc
Meiji Seika Pharma Co Ltd
Merck KGaA
Olympus Corp
RF Medical Co Ltd
Sun Pharmaceutical Industries Ltd
Who should buy this report?
The Europe Lung Cancer Therapy Market report is valuable for diverse stakeholders, including:
Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.
Essentially, anyone involved in or considering involvement in the Europe Lung Cancer Therapy Market value chain can benefit from the information contained in a comprehensive market report.